Compare SEED & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEED | TCRT |
|---|---|---|
| Founded | 1997 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 7.8M |
| IPO Year | 2005 | 2025 |
| Metric | SEED | TCRT |
|---|---|---|
| Price | $0.69 | $1.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.3K | ★ 1.6M |
| Earning Date | 05-21-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $0.72 |
| 52 Week High | $1.73 | $4.50 |
| Indicator | SEED | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 44.64 |
| Support Level | $0.67 | $1.61 |
| Resistance Level | $1.07 | $2.09 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 19.11 | 10.16 |
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.